Centessa Pharmaceuticals (CNTA) Depreciation & Amortization (CF) (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Depreciation & Amortization (CF) of $239000.0 for Q1 2026, up 10.14% year-over-year from $217000.0 in Q1 2025, and down 0.83% quarter-over-quarter from $241000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $239000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $239000.0, up 10.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $943000.0 (up 2.61% YoY), and the FY2025 annual result was $921000.0, down 2.23% from the prior year.
- Depreciation & Amortization (CF) declined to $239000.0 in Q1 2026 per CNTA's latest filing, from $241000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $246000.0 in Q4 2023 and troughed at $28000.0 in Q1 2022.
- A 5-year average of $179000.0 and a median of $236000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 1300.0% in 2022, then slipped 9.58% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $36000.0 in 2022, then soared by 583.33% to $246000.0 in 2023, then retreated by 6.5% to $230000.0 in 2024, then grew by 4.78% to $241000.0 in 2025, then decreased by 0.83% to $239000.0 in 2026.
- Business Quant data shows CNTA's Depreciation & Amortization (CF) at $239000.0 in Q1 2026, $241000.0 in Q4 2025, and $237000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Centessa Pharmaceuticals | 6.10 Bn | 6.10 Bn | - | 239,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 239,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Dec 31, 2025 | 241,000.00 |
| Dec 31, 2025 | 241,000.00 |
| Sep 30, 2025 | 237,000.00 |
| Sep 30, 2025 | 237,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Dec 31, 2024 | 230,000.00 |
| Dec 31, 2024 | 230,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Jun 30, 2024 | 236,000.00 |
| Jun 30, 2024 | 236,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 246,000.00 |
| Dec 31, 2023 | 246,000.00 |